HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House FDA reform national uniformity provision acknowledges state tort rights.

This article was originally published in The Rose Sheet

Executive Summary

HOUSE FDA REFORM NATIONAL UNIFORMITY PROVISION ACKNOWLEDGING STATE TORT RIGHTS is included in a revised draft of Rep. Richard Burr's (R-N.C.) drugs and biologics bill (HR 3199). The new draft, released July 10, includes a clarification, which states that "nothing in the [national uniformity] section shall be construed to modify or otherwise affect any action or the liability of any person under the generally applicable tort law of any state."

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel